Our milestone-based funding approach allows us to efficiently allocate capital while ensuring that development constantly progresses.
Deep domain expertise
atai’s companies benefit from our extensive mental health drug development expertise. We continuously leverage economies of scope across our programs.
Enabling platform technologies
Leveraging proprietary technology to accelerate drug discovery, reposition existing molecules with big data approaches, and improve patient outcomes with digital therapeutics.
At atai, we believe that disruptive innovation requires long-term entrepreneurial incentives. Our therapies are developed in entrepreneur-led and decentralized companies with lean and agile teams.
By streamlining internal processes like accounting and HR, we allow our companies’ scientific founders to focus on what really matters — the science.